

Nature of Hydrogen Bonding in the Interaction of 4-Aminobenzoic, Nicotinic and Sulfonilic Acids With 4-Aminopyridine

A.Sinthiya

Department of Physics, Srimad andavan arts and science college (Autonomous)

ABSTRACT

Even though N-H...O bond is considered as strong hydrogen bonding, based on the D-H<<H-A distance and the angle between them, the crystal packing of $C_7H_6NO_2 \cdot C_5H_7N_2^+ \cdot 2H_2O$, has three weak N-H...O bonds with mean distance value as $0.88\text{Å} << 2.08\text{Å}$, the angle between them lie in the ranges $143^\circ - 150^\circ$ and has seventeen strong hydrogen bonding with good donor and good acceptor. The crystal packing of $C_5H_7N_2^+ \cdot C_6H_4NO_2^-$ has one weak hydrogen bonding with distance $0.92\text{Å} << 2.49\text{Å}$, angles 127° for N-H...O bonding and three strong hydrogen bonding. The crystal packing of $C_5H_7N_2^+ \cdot C_6H_4NO_3S \cdot C_6H_4NO_3S \cdot H_2O$ has three weak N-H...O hydrogen bonding with distances ranges between $0.90\text{Å} << 2.96\text{Å}$, angles ranging from $131^\circ - 144^\circ$, one C-H... π weak hydrogen bonding with 129° angles and four strong hydrogen bonding. Hence the presence of weak hydrogen bonding C-H... π of $C_5H_7N_2^+ \cdot C_6H_4NO_3S \cdot C_6H_4NO_3S \cdot H_2O$ shows that it can most significantly contribute to the interaction with the protein in drug design approach and other two complexes have fewer possibilities by having weak N-H...O bonding for interaction of protein for auto immune disorder like multiple sclerosis than the other heterocyclic complexes.

KEYWORDS : 4-aminobenzoic acid, nicotinic acid, Sulfonilic acid 4-aminopyridine, drug design, MS.

1. Introduction


The 4-Aminopyridine (fampridine) is used in the treatment of neurological ailments, such as multiple sclerosis (MS), with tests showing that fampridine improves motor function in MS patients [Schwid et al., 1997]. The importance of weak C-H...O hydrogen bonds in macromolecules is a well-established phenomenon (Desiraju and Steiner 1999). The earlier works described their significance, as supporting interactions of stronger N-H...O and O-H...O bonds in protein-ligand complexation (Sarkhel and Desiraju 2004; Panigrahi and Desiraju 2007). Based on the assumption that strong hydrogen bonding in drug-receptor interactions are thus inherently assisted by weak hydrogen bonds (Aparna et al 2005), the aim of the present study is to analyze the importance of strong and weak hydrogen bonds in drug-DNA complexes. Hydrogen bonds formed by good donors (O-H, N-H) and good acceptors (N, O, halide) are labeled 'strong'. Accordingly O-H...O, N-H...O, O-H...N and N-H...N hydrogen bonds will be termed 'strong' whatever be their energy stabilization, geometrical parameters or furcation status. (Nishio et al 1998). The reason we refer to Jeffrey's middle category as 'strong' originates from supramolecular chemistry considerations. By 'strong' we mean hydrogen bonds that are able to control crystal and supramolecular structure effectively (Panigrahi and Desiraju 2007). Hydrogen bonds between polarized atoms play a crucial role in protein interactions and are often used in drug design, which usually neglects the potential of C-H...O hydrogen bonds. A striking example is the hydroxyl group of the ligand that acts as an H bond donor and acceptor, leading to a synergy between classical and C-H...O hydrogen bonds. This interaction introduces both specificity and affinity within the hydrophobic ligand pocket. The similarity of intraprotein and protein-ligand C-H...O interactions suggests that such bonds should be considered in rational drug design approaches (Klaholz B et al 2002).

There are two factors contributing to the strength of hydrogen bonds: the charges on the donor and acceptor groups which deshield the proton or increase the electron density of the acceptor, and the configurationally constraint that forces a close contact between the donor and acceptor [8]. Hydrophilic regions tend to surround hydrophobic areas which gather into the central hydrophobic core. It has tendency to biological molecule. Biological molecule interacts mainly via electrostatic forces including hydrogen bonds or hydrogen bonding networks often formed through water molecules [9]. Depending on the structure of the substance and acceptor, the binding mechanism may proceed in nontrivial mechanism of protecting stable complex formation between drugs and non-specific targets [10]. The H-bond of C-H...O plays expected role in biomolecules [11,12,13]. Recently also the X-H... π H-bonds (for X=O and C) were detected and it was shown that contrary to expectation they can significantly contribute to the stability of biomacromolecules and molecular clusters [14,15].

2. Materials and methods:

The crystal structures of 4-aminopyridinium 4-aminobenzoate dehydrate ($C_7H_6NO_2 \cdot C_5H_7N_2^+ \cdot 2H_2O$), 4-aminopyridinium nicotinate ($C_5H_7N_2^+ \cdot C_6H_4NO_2^-$) and 4-Aminopyridinium 4-aminobenzenesulfonate 4-ammonio-benzenesulfonate monohydrate ($C_5H_7N_2^+ \cdot C_6H_4NO_3S \cdot C_6H_4NO_3S \cdot H_2O$), were taken for the hydrogen bonding analysis from the research articles published in the International union of crystallography journals [16,17]. Figure 1 show the molecular structure for the analyzed complexes.

Figure 1: Molecular structures of selected three heterocyclic complexes

**3. Result and discussions**

H-bonds play a key role in determining the shapes, properties and functions of bio molecules [14,15]. In general, the strongest hydrogen bond donors pair off with strongest hydrogen bond acceptors. Similarly pairing process is repeated until all the hydrogen bond donors and acceptors have been utilized. However when a system contains excess donors or acceptors, at least two hydrogen-bonding strategies are available to accommodate the mismatch [Hanton, Hunter & Purvis, 1992] (i) change in hybridization or (ii) the formation of hydrogen bonds involving the π system of an aromatic group as the acceptor. Several examples of the formation of intermolecular X-H... bonds for X=O or N have been observed where there is a deficiency of sterically accessible acceptors site of the conventional type [Hanton, Hunter & Purvis, 1992, Rzepa, Slawin & Williams 1991]

Table 1 show the structural detail of the selected three heterocyclic complexes and table 2 show the total number of hydrogen bonding present in the crystal packing.

Table 1: Structural detail of the selected three heterocyclic complexes

S.No	Details	$C_7H_6NO_2 \cdot C_5H_7N_2^+ \cdot 2H_2O$	$C_5H_7N_2^+ \cdot C_6H_4NO_2^-$	$C_5H_7N_2^+ \cdot C_6H_4NO_3S \cdot C_6H_4NO_3S \cdot H_2O$
1	Interaction by	Pyridine ring group	Pyridine ring group	Amine group and pyridine ring group
2	Anion	Two 4-aminobenzoate	One nicotinate	One 4-aminobenzene sulfonate
3	Cation	Two 4-aminopyridine	One 4-aminopyridine	One 4-aminopyridinium
4	Other molecules	Four water molecules	One carboxyl group	One half of two water molecules

5	Zwitterion	-	-	One 4-ammoniobenzenesulfonate
---	------------	---	---	-------------------------------

Table 2: Total number of hydrogen bonds present in the complexes

S.No	Complexes	N-H...O	O-H...O	N-H...N	N-H...S	C-H... π
1	$C_5H_7NO_2^+ \cdot C_6H_7N_2^+ \cdot 2H_2O$	12	8	--	--	--
2	$C_5H_7N_2^+ \cdot C_6H_7NO_2^-$	3	--	1	--	--
3	$C_5H_7N_2^+ \cdot C_6H_6NO_3S^- \cdot C_6H_7NO_3S^- \cdot H_2O$	8	1	--	1	1

Compound I has 20 hydrogen bonds, compound II has 4 hydrogen bonds and compound III has 11 hydrogen bonds. In compound $C_5H_7NO_2^+ \cdot C_6H_7N_2^+ \cdot 2H_2O$, the hydrogen bonding N4B-H4B...O9B has D-H<< H-A as bond distances $0.88\text{Å} << 1.99\text{Å}$ with 143° bond angles, the hydrogen bonding N4D-H4D...O9C has D-H<< H-A as bond distances $0.88\text{Å} << 2.08\text{Å}$ with 146° bond angles and the hydrogen bonding N4D-H4D...O8C has D-H<< H-A as bond distances $0.88\text{Å} << 2.09\text{Å}$ with 150° bond angles. The crystal packing of $C_5H_7N_2^+ \cdot C_6H_7NO_2^-$ has one weak N1-H1...O15 hydrogen bonding D-H<< H-A with distance $0.92\text{Å} << 2.49\text{Å}$, angles 127° and three strong hydrogen bonding. The crystal packing of $(C_5H_7N_2^+ \cdot C_6H_6NO_3S^- \cdot C_6H_7NO_3S^- \cdot H_2O)$ has hydrogen bonding C12-H12A... π , N3-H1N3-O2W, N3-H1N3...O1 and N2-H1N2...S1 have D-H<< H-A bond distances as $0.93\text{Å} << 2.96\text{Å}$, $0.90\text{Å} << 2.26\text{Å}$, $0.90\text{Å} << 2.13\text{Å}$ and $0.90\text{Å} << 2.84\text{Å}$ with bond angles $129^\circ, 131^\circ, 140^\circ$, and 144° respectively.

4. Conclusion:

From the XRD pattern of selected three heterocyclic complexes we propose that the presence of weak hydrogen bonding C-H... π of $C_5H_7N_2^+ \cdot C_6H_6NO_3S^- \cdot C_6H_7NO_3S^- \cdot H_2O$ shows that it can most significantly contribute to the interaction with the protein in drug design approach and other two complexes have fewer possibilities by having weak N-H...O bonding for interaction of protein for autoimmune disorder like multiple sclerosis than the other heterocyclic complexes.

REFERENCES

- Schwid, S. R., Petrie, M. D., McDermott, M. P., Tierney, D. S., Mason, D. H. & Goodman, A. D. (1997). *Neurology*, 48, 817–821.
- Desiraju G R and Steiner T 1999 *The weak hydrogen bond in structural chemistry and biology* (Oxford: Oxford University Press)
- Sarkhel S and Desiraju G R 2004 N-H...O, O-H...O, and C-H...O hydrogen bonds in protein–ligand complexes: strong and weak interactions in molecular recognition; *Proteins* 54 247–259
- Panigrahi S K and Desiraju G R 2007 Strong and weak hydrogen bonds in the protein–ligand interface; *Proteins* 67 128–141.
- Aparna V, Rambabu G, Panigrahi S K, Sarma J A R P and Desiraju G R 2005 Virtual screening of 4-anilinoquinazoline analogs as EGFR kinase inhibitors: importance of hydrogen bonds in the evaluation of poses and scoring functions; *J. Chem. Inf. Model.* 45 725–738
- Nishio M, Hirota M and Umezawa Y 1998 The CH/p interaction. Evidence, nature, and consequences (New York: Wiley-VCH, Inc.)
- Klaholz B, Moras D, 2002. C-H...O hydrogen bonds in the nuclear receptor RARGamma—a potential tool for drug selectivity. *Structure*, Sep;10(9):1197-204.
- Study of hydrogen bonding properties with Ab initio calculations, Neutron scattering spectroscopy and 1H NMR. Yanmei Lan, UMI dissertation published, 2007, United states.
- www.iupac.org/publications/Col/medicinal_chemistry
- Pharmacological aspects of molecular recognition. F.S. Dukhovich, Nova publishers. 2005.
- G.A. Jeffrey. *An introduction to hydrogen bonding*, Oxford university Press New York 1997.
- G.R. Desiraju and T. Steiner. *The weak hydrogen bond*, Oxford university press, New York, 1999.
- S. Scheiner, *Hydrogen bonding*, Oxford university press, New York, 1997.
- N. Klusak, Z. Havlas et al., *Chem. Biol.*, 2003, 10, 331
- J. Braun et al., *J. Phys. Chem., A*, 2003, 107, 3918.
- 4-Aminopyridinium 4-aminobenzoate dihydrate and 4-aminopyridinium nicotinate; *Acta Cryst.* (2009). C65, page : o361–o364
- 4-Aminopyridinium 4-aminobenzenesulfonate 4-ammoniobenzenesulfonate monohydrate; *Acta Cryst.* (2008). E64, page : o697–o698
- Hanton L.R., Hunter, C.A. & Purvis, D.H., *J. Chem. Soc. Chem. Commun.* 1992, pp.1134-1136
- Rzepa, H.S., Webb, M.L., Slawin, A.M.Z. & Williams, D.J., *J. Chem. Soc. Chem. Commun.* 1991, pp.765-768.